Can it be completely cured by taking tremelimumab?

For the treatment of hepatocellular carcinoma (HCC), tremelimumab is usually given as a single dose. For the treatment of non-small cell lung cancer, it is usually administered every 3 weeks for 4 doses (Cycles 1 to 4), then as a single dose at Week 16 (Cycle 6). Although temsitumumab can enhance the immune system's ability to attack tumor cells, not all patients will achieve a complete cure. Treatment results may vary on an individual basis, and some patients may show a better response to the drug while others may not.

Temtumumab, an immune checkpoint inhibitor , is a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blocking human IgG2 monoclonal antibody can produce significant therapeutic effects in some cases. If any symptoms occur during the infusion, such as chills, flushing, trembling, dizziness, shortness of breath, wheezing, fever, itching, rash, the doctor may slow down the infusion rate, permanently or temporarily stop temimumab injection treatment, or provide additional drug treatment based on the response to the drug and any side effects encountered. .

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.